热带病与寄生虫学 ›› 2024, Vol. 22 ›› Issue (3): 157-163.doi: 10.3969/j.issn.1672-2302.2024.03.006
收稿日期:
2024-03-02
出版日期:
2024-06-20
发布日期:
2024-06-28
通信作者:
王勇,E-mail: 作者简介:
戴昱婕,女,硕士在读,研究方向:感染与免疫研究。E-mail: 基金资助:
DAI Yujie(), SUN Jierui, HU Tingting, LIU Xinjian(
), WANG Yong(
)
Received:
2024-03-02
Online:
2024-06-20
Published:
2024-06-28
Contact:
WANG Yong, E-mail: 摘要:
目的 探讨吡喹酮(praziquantel, PZQ)对肝癌细胞增殖、迁移和凋亡的影响及其作用机制。方法 体外培养Hep3B人肝癌细胞株和Hepa1-6小鼠肝癌细胞株,分为正常对照组、PZQ处理组、5-羟色胺2B(5-HT2B)受体抑制剂组(RS127445组)、5-HT2B受体抑制剂+PZQ处理组(RS127445+PZQ处理组)。采用实时荧光定量 PCR(qRT-PCR)检测Hep3B人肝癌细胞株和Hepa1-6小鼠肝癌细胞株中5-HT2B 受体mRNA相对表达水平,CCK-8法检测细胞增殖情况,划痕实验检测细胞迁移能力,流式细胞术检测细胞凋亡率,western blot法检测Bax、Bcl-2凋亡相关蛋白表达量。结果 Hep3B人肝癌细胞株和Hepa1-6小鼠肝癌细胞株5-HT2B受体mRNA相对表达水平正常对照组为1.02±0.09和1.01±0.20,PZQ处理组为1.36±0.16和1.66±0.16,经PZQ处理后5-HT2B受体mRNA相对表达水平均增加(t=3.22、5.07,P均<0.05)。PZQ处理组两种细胞株48 h细胞增殖率为(74.00±4.58)%和(77.00±5.29)%,低于正常对照组(t=9.88、7.47,P均<0.01);72 h细胞增殖率为(71.00±6.08)%和(67.33±7.57)%,低于正常对照组(t=7.87、6.00,P均<0.05)和RS127445+PZQ处理组(t=5.48、3.48,P均<0.05)。PZQ处理组两种细胞株48 h细胞迁移率为(52.91±3.15)%和(17.28±1.78)%,低于正常对照组(t=7.86、13.46,P均<0.01);72 h细胞迁移率为(58.79±3.25)%和(22.29±5.87)%,低于正常对照组(t=11.65、9.57,P均<0.05)和RS127445+PZQ处理组(t=3.13、6.97,P均<0.05)。PZQ处理组两种细胞株72 h细胞凋亡率为(16.13±0.66)%和(20.70±2.85)%,高于正常对照组和RS127445+PZQ处理组(t=27.82、5.65、9.54、4.10,P均<0.01);Bax相对蛋白表达水平分别为1.70±0.18和2.23±0.14,高于正常对照组(t=2.83、7.89,P均<0.05)和RS127445+PZQ处理组(t=9.40、5.25,P均<0.05);Bcl-2相对蛋白表达水平分别为0.52±0.17和0.53±0.02,低于正常对照组(t=3.57、8.39,P均<0.05)和RS127445+PZQ处理组(t=12.09、6.12,P均<0.05)。结论 PZQ可通过5-HT2B受体对肝癌细胞的增殖、迁移和凋亡造成影响。
中图分类号:
戴昱婕, 孙捷睿, 胡婷婷, 刘新建, 王勇. 吡喹酮通过5-HT2B受体对肝癌细胞恶性生物学行为的影响[J]. 热带病与寄生虫学, 2024, 22(3): 157-163.
DAI Yujie, SUN Jierui, HU Tingting, LIU Xinjian, WANG Yong. Effects of praziquantel on the malignant biological behavior of hepatocellular carcinoma cells through 5-HT2B receptor[J]. Journal of Tropical Diseases and Parasitology, 2024, 22(3): 157-163.
[1] | Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends,risk,prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604. |
[2] |
Mortezaee K. Human hepatocellular carcinoma:protection by melatonin[J]. J Cell Physiol, 2018, 233(10):6486-6508.
doi: 10.1002/jcp.26586 pmid: 29672851 |
[3] |
Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy[J]. J Gastrointest Oncol, 2017, 8(2):256-265.
doi: 10.21037/jgo.2016.09.07 pmid: 28480065 |
[4] | Cioli D, Pica-Mattoccia L, Basso A, et al. Schistosomiasis control: praziquantel forever?[J]. Mol Biochem Parasitol, 2014, 195(1):23-29. |
[5] | Chan JD, Zarowiecki M, Marchant JS. Ca2+ channels and praziquantel: a view from the free world[J]. Parasitol Int, 2013, 62(6):619-628. |
[6] |
Chan JD, Cupit PM, Gunaratne GS, et al. The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand[J]. Nat Commun, 2017, 8(1):1910.
doi: 10.1038/s41467-017-02084-0 pmid: 29208933 |
[7] | Yahya NA, Lanham JK, Sprague DJ, et al. Molecular and cellular basis of praziquantel action in the cardiovascular system[J]. Am J Physiol Cell Physiol, 2023, 324(2):C573-C587. |
[8] | Nogueira RA, Lira MGS, Licá ICL, et al. Praziquantel: an update on the mechanism of its action against schistosomiasis and new therapeutic perspectives[J]. Mol Biochem Parasitol, 2022, 252:111531. |
[9] | Wu ZH, Lu MK, Hu LY, et al. Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth[J]. PLoS One, 2012, 7(12):e51721. |
[10] | 刘劲峰. 吡喹酮抑制肝星状细胞TGF-β/Smad信号通路抗肝纤维化作用机制[D]. 南京: 南京医科大学, 2016. |
[11] |
梁幼生. 我国血吸虫对吡喹酮抗药性研究之概要[J]. 中国热带医学, 2019, 19(7):603-607.
doi: 10.13604/j.cnki.46-1064/r.2019.07.01 |
[12] |
王伟, 赵成思, 缪婷婷, 等. 吡喹酮治疗对日本血吸虫感染小鼠脾巨噬细胞增殖和炎症反应的抑制作用[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(3):263-270.
doi: 10.12140/j.issn.1000-7423.2020.03.002 |
[13] | Sun Q, Mao RF, Wang DL, et al. The cytotoxicity study of praziquantel enantiomers[J]. Drug Des Devel Ther, 2016, 10:2061-2068. |
[14] | 袁轩, 张苏阳, 姚甲凯, 等. 吡喹酮异构体对肝星状细胞系LX-2增殖及活化的作用[J]. 中国血吸虫病防治杂志, 2022, 34(1):75-80. |
[15] | Park SK, Friedrich L, Yahya NA, et al. Mechanism of praziquantel action at a parasitic flatworm ion channel[J]. Sci Transl Med, 2021, 13(625):eabj5832. |
[16] | Le Clec’h W, Chevalier FD, Mattos ACA, et al. Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel[J]. Sci Transl Med, 2021, 13(625):eabj9114. |
[17] | Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors[J]. Pharmacol Biochem Behav, 2002, 71(4):533-554. |
[18] |
Ebrahimkhani MR, Oakley F, Murphy LB, et al. Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease[J]. Nat Med, 2011, 17(12):1668-1673.
doi: 10.1038/nm.2490 pmid: 22120177 |
[19] | Koh SJ, Kim JM, Kim IK, et al. Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2011, 301(1):G9-G19. |
[20] |
Collet C, Schiltz C, Geoffroy V, et al. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation[J]. FASEB J, 2008, 22(2):418-427.
pmid: 17846081 |
[21] |
Fatima S, Shi XK, Lin ZS, et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing β-catenin[J]. Mol Oncol, 2016, 10(2):195-212.
doi: 10.1016/j.molonc.2015.09.008 pmid: 26474915 |
[22] | Bai CF, Liu JC, Zhao R, et al. Role of 5-HT 2B receptors in cardiomyocyte apoptosis in noradrenaline-induced cardiomyopathy in rats[J]. Clin Exp Pharmacol Physiol, 2010, 37(7):e145-e151. |
[23] |
Bharti S, Rani N, Bhatia J, et al. 5-HT2B receptor blockade attenuates β-adrenergic receptor-stimulated myocardial remodeling in rats via inhibiting apoptosis: role of MAPKs and HSPs[J]. Apoptosis, 2015, 20(4):455-465.
doi: 10.1007/s10495-014-1083-z pmid: 25544272 |
[24] | Yang YQ, Wen ZY, Liu XY, et al. Current status and prospect of treatments for recurrent hepatocellular carcinoma[J]. World J Hepatol, 2023, 15(2):129-150. |
[25] |
Li WL, Wang D, Li MJ, et al. Emodin inhibits the proliferation of papillary thyroid carcinoma by activating AMPK[J]. Exp Ther Med, 2021, 22(4):1075.
doi: 10.3892/etm.2021.10509 pmid: 34447468 |
[26] | Li FY, Hou XY, Tan HZ, et al. Current status of schistosomiasis control and prospects for elimination in the Dongting Lake Region of the People’s republic of China[J]. Front Immunol, 2020, 11:574136. |
[27] |
Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference[J]. Science, 2009, 324(5933):1394-1395.
doi: 10.1126/science.1169920 pmid: 19520944 |
[28] |
Sachs RE, Ginsburg PB, Goldman DP. Encouraging new uses for old drugs[J]. JAMA, 2017, 318(24):2421-2422.
doi: 10.1001/jama.2017.17535 pmid: 29204602 |
[1] | 黄星炯, 黄显泽, 班贡生, 陆丽艳, 梁美群, 林世保. 三苯双脒治疗华支睾吸虫病的效果观察[J]. 热带病与寄生虫学, 2023, 21(1): 48-51. |
[2] | 杨筱萌, 罗语思, 张科. 病毒感染对细胞凋亡影响的研究进展[J]. 热带病与寄生虫学, 2022, 20(5): 284-289. |
[3] | 黄星炯, 张国汉, 梁美群, 黄显泽, 黄雅铃, 危国强. 吡喹酮治疗门诊华支睾吸虫病患者的疗效观察[J]. 热带病与寄生虫学, 2021, 19(4): 224-. |
[4] | 杨琼. 吡喹酮与槟榔-南瓜子治疗带绦虫病的疗效比较[J]. 热带病与寄生虫学, 2021, 19(1): 32-35. |
[5] | 卢萍,尤璐,华海涌,汪伟. 吡喹酮治疗晚期血吸虫病肝纤维化效果的临床研究[J]. 热带病与寄生虫学, 2015, 13(4): 204-207. |
[6] | 卢萍,尤璐,华海涌. 日本血吸虫病低度流行区吡喹酮薄膜衣片临床疗效及不良反应评价[J]. 热带病与寄生虫学, 2015, 13(3): 169-171. |
[7] | 卢萍,汪伟*,曲国立,戴建荣,梁幼生. 3 种青蒿素衍生物对日本血吸虫吡喹酮抗性株童虫的体内作用效果观察[J]. 热带病与寄生虫学, 2014, 12(2): 67-69,72. |
[8] | 孙瑜. 19例脑型血吸虫病临床诊断与治疗[J]. 热带病与寄生虫学, 2014, 12(1): 39-40,封四. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||